Evaluation of efficacy and effectiveness of live attenuated zoster vaccine

Journal of Preventive Medicine and Hygiene

Volumn 55, Issue 4, 2014, Pages 130-136

  Gabutti, G ^a   ValeNte, N ^a   Sulcaj, N ^a   StefaNati, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Herpes zoster; Prevention; Vaccine

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE;

CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HEADACHE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE SWELLING; NONHUMAN; PAIN; PRURITUS; REVIEW; SKIN REDNESS; SWELLING; VACCINATION; NEURALGIA, POSTHERPETIC; TREATMENT OUTCOME;

HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC; TREATMENT OUTCOME;

EID: 84938684550     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Bonanni P, Breuer J, Gershon A, et al. Varicella vaccination in Europe-taking the practical approach. BMC Medicine 2009; 7:26.
2. Davison AJ Molecular evolution of alphaherpesviruses. In: Arvin AM, Gershon AA, eds. Varicella-Zoster Virus: Virology and Clinical Management. Cambridge: Cambridge University Press, 2000, pp. 25-50.
3. Mori I, Nishiyama Y. Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another? Rev Med Virol 2005; 15:393-406.
4. Kim HK Herpes Zoster Vaccination. Korean J Pain 2013; 26:242-8.
5. Arvin AM, Moffat JF, Redman R. Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res 1996; 46:263-309.
6. Quinlivan M, Breuer J. Molecular studies of varicella zoster virus. Rev Med Virol 2006; 16:225-50.
7. Public Health Agency of Canada. Varicella-zoster virus. Pathogen safety data sheet-infectious substances. Available at http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/var-zo-eng.php; (accessed June 2014).
8. Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster. The European view. Am J Clin Dermatol 2005; 6:317-25.
9. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56.
10. Kawai K, Gebremeskei BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4:e004833.
11. Arvin AM, Koropchak CM, Williams BR, et al. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 1986; 154:422-9.
12. Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 (S1):S2-7.
13. Ihara T, Kato T, Torigoe S, et al. Antibody response determined with antibody-dependent cellmediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatr Jpn 1991; 33:43-9.
14. Asada H, Nagayama K, Okazaki A, et al. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. J Dermatol Sci 2013; 69:243-9.
15. Levin MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol 2010; 48(SUPPL. 1):S14-9.
16. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
17. Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS One 2013; 8:e66485.
18. Salleras M, Dominguez A, Soldevila N, et al. Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 2011; 29:7602-5.
19. Gaillat J, Gajdos V, Launay O, et al. Does monastic life predispose to the risk of Saint Anthony'sfire (herpes zoster)? Clin Infect Dis 2011; 53:405-10.
20. Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012 Jul 15; 206:190-6.
21. Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005; 6:317-25.
22. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347:340-6.
23. Johnson R, McElhaney J, Pedalino B, et al. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007; 11(SUPPL. 2):S43-8.
24. Franco E, Gabutti G, Bonanni P, et al. Herpes Zoster and its prevention in Italy. Scientific consensus statement. Ig Sanita Pubbl 2014; 70:111-27.
25. Arvin AM Varricella-zoster virus. Clin Microbiol Rev 1996; 9:361-81.
26. Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9(SUPPL. 1):S37-44.
27. Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19:471-5.
28. van Seventer R, Sadosky A, Lucero M, et al. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006; 35:132-7.
29. Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25:991-1006.
30. Cunningham AL, Breuer J, Dwyer DE, et al. The prevention and management of herpes zoster. Med J Aust 2008; 188:171-6.
31. Zaal MJ, Volker-Dieben HJ, D'Amaro J. Prognostic value of Hutchinson's sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol 2003; 241:187-91.
32. Tojo K, Onozawa T, Toyohara K, et al. Herpes zoster ophthalmicus with delayed contralateral hemiparesis. Jpn J Med 1990; 29:99-103.
33. Carneiro AV, Ferro J, Figueiredo C, et al. Herpes zoster and contralateral hemiplegia in an African patient infected with HIV-1. Acta Med Port 1991; 4:91-2.
34. Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology 2010; 74:792-7.
35. Breuer J, Pacou M, Gauthier A, et al. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology 2014; 82:206-12.
36. Langan SM, Minassian C, Smeeth L, et al. Risk of stroke following Herpes Zoster: a self-controlled case-series study. Clin Infect Dis 2014; 58:1497-503.
37. Dworkin RH Post-herpetic neuralgia. Herpes 2006; 13(SUPPL. 1):21A-7.
38. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347:340-6.
39. Galluzzi KE Management strategies for herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc 2007; 107(3 Suppl 1):S8-13.
40. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; 15;(2):CD006866.
41. Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing Post-Herpetic Neuralgia. Cochrane database Syst Rev 2014; 2:CD006866.
42. Oxman MN Clinical manifestation of herpes zoster. In: Arvin AM, Gerson AA, eds. Varicella zoster virus: virology and clinical management. Cambridge, UK: Cambridge University press; 2000, pp. 246-75.
43. Drolet M, Brisson M, Schmader K, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010; 11:1211-21.
44. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9.
45. Weaver BA The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States. J Am Osteopath Assoc 2007; 107(3 Suppl 1):S2-7.
46. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20:748-53.
47. Joon Lee T, Hayes S, Cummings DM, et al. Herpes zoster knowledge, prevalence, and vaccination rate by race. J Am Board Fam Med 2013; 26:45-51.
48. Pinchinat S, Ana M Cebriàn-Cuenca, Hélène Bricout, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infectious Diseases 2013; 13:170.
49. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 2011; 174:1054-61.
50. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4:26-33.
51. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of Herpes Zoster and Post-Herpetic Neuralgia in Italy: a retrospective population-based study. BMC Infect Dis 2010; 10:230.
52. Franco E, Perinetti E, Marchettini P, et al. Proportion of PostHerpetic Neuralgia among patients with Herpes Zoster in Italy - a multicenter prospective observational study (Heroes study). European Geriatric Medicine 2013; 4:S115-6.
53. Gabutti G, Serenelli C, Cavallaro A, et al. Herpes zoster associated hospital admissions in italy: review of the hospital discharge forms. Int J Eniron Res Public Health 2009; 6:2344-53.
54. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197(SUPPL. 2):S207-15.
55. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33:62-9.
56. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6:356-63.
57. Oxman MN Immunization to reduce the frequency and severity of Herpes Zoster and its complications. Neurology 1995; 45(12 Suppl 8):S41-6.
58. Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178(SUPPL. 1):S109-12.
59. Trannoy E, Berger R, Holländer G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of Varicella Zoster Virus: a randomized, controlled, dose-response trial. Vaccine 2000; 18:1700-6.
60. Breuer J. Vaccination to prevent varicella and shingles. J Clin Pathol 2001; 54:743-7.
61. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in Varicel-la-Zoster Virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336-44.
62. Herpes Zoster vaccine (live). Zostavax Summary of product characteristics 2013. Revision 18 December 2013.
63. Oxman MN1, Levin MJ, Johnson GR, et al. A vaccine to prevent Herpes Zoster and Post-Herpetic Neuralgias in older adults. N Engl J Med 2005; 352:2271-84.
64. Schmader KE, Levin MJ, Gnann JW jr, et al. Efficacy, safety and tolerability of Herpes Zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8.
65. Hope-Simpson RE. The nature of herpes zoster: a long-term stud and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
66. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56.
67. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of Zoster vaccine in the Shingles Prevention Study and the short-term persistence sub-study. Clin Infect Dis 2012; 55:1320-8.
68. EMA SPC Zostavax available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Informaton/human/000674/WC500053462.pdf
69. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Jama 2011; 305:160-6.
70. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308:43-9.
71. Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Medicine 2013; 10(4):e1001420.
72. https://clinicaltrials.gov/ct2/show/NCT01600079?term=NCT01600079&rank=1)
73. Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-8.
74. Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥ 60 years old. Hum Vac 2011; 7:1130-6.
75. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of Herpes Zoster. Vaccine 2010; 28:4204-9.
76. Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013; 208:559-63.
77. CDC. Prevention of Herpes Zoster. Recommendations of the Advisory Committee on immunization practices (ACIP). MMWR 2008; 57:1-29.
78. Tseng HF, Schmid DS, Harpaz R, et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis 2014; 58:1125-8.
79. EUnetHTA. Zostavax for the prevention of herpes zoster and post-herpetic neuralgia. Pilot assessment using the draft HTA Core Model for rapid relative effectiveness assessment. Version 4.0 September 2013 http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Zostavax-main%20report%20including%20appendices-20130922.pdf (last accessed June 2014).